At the end of the beginning: immunotherapies as living drugs

Nat Immunol. 2019 Aug;20(8):955-962. doi: 10.1038/s41590-019-0452-8.

Authors

Ellen G Feigal^{1

2}, Natalie D DeWitt^{3

4}, Cathy Cantilena⁵, Carl Peck^{3

6}, David Stroncek⁵

Affiliations

¹ NDA Partners, Rochelle, VA, USA. [email protected].
² Sandra Day O'Connor College of Law, Arizona State University, Phoenix, AZ, USA. [email protected].
³ NDA Partners, Rochelle, VA, USA.
⁴ Accendo Scientific, Des Moines, IA, USA.
⁵ National Institutes of Health, Bethesda, MD, USA.
⁶ University of California San Francisco, San Francisco, CA, USA.

PMID: 31308544
DOI: 10.1038/s41590-019-0452-8

No abstract available

MeSH terms

Cell- and Tissue-Based Therapy / adverse effects
Cell- and Tissue-Based Therapy / methods*
Humans
Immunotherapy, Adoptive / adverse effects
Immunotherapy, Adoptive / methods*
Neoplasms / therapy*
T-Lymphocytes / transplantation
Transplantation, Autologous / methods